Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Context Therapeutics Inc. (CNTX:NASDAQ), powered by AI.
Context Therapeutics Inc. is currently trading at $0.65. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Context Therapeutics Inc. on Alpha Lenz.
Context Therapeutics Inc.'s P/E ratio is -1.7.
“Context Therapeutics Inc. trades at a P/E of -1.7 (undervalued) with modest ROE of -46.4%.”
Ask for details →Context Therapeutics Inc. is a biopharmaceutical company focused on advancing treatments for hormone-driven female cancers. Primarily, the company develops investigational therapies targeting estrogen receptors, aiming to innovate in areas of significant unmet medical need. Context Therapeutics operates within the life sciences and biotechnology sectors, engaging in research and development to combat cancers like breast and ovarian cancer. The company's approach involves optimizing therapeutic outcomes through cutting-edge research, clinical trials, and strategic collaborations. With a strong commitment to patient-centered care, Context Therapeutics impacts the healthcare industry by striving to provide more effective and personalized treatment options for female cancer patients. Established in an era of increased focus on women's health, Context Therapeutics plays a vital role in the continued evolution and enhancement of oncology treatment solutions in the financial market.
“Context Therapeutics Inc. trades at a P/E of -1.7 (undervalued) with modest ROE of -46.4%.”
Ask for details →Context Therapeutics Inc. (ticker: CNTX) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 12 employees. Market cap is $62M.
The current price is $0.65 with a P/E ratio of -1.71x and P/B of 1.02x.
ROE is -46.39%.